Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Receivables (2018 - 2025)

Dna X's Receivables history spans 8 years, with the latest figure at $13.3 million for Q3 2025.

  • Quarterly results put Receivables at $13.3 million for Q3 2025, up 126.7% from a year ago — trailing twelve months through Sep 2025 was $13.3 million (up 126.7% YoY), and the annual figure for FY2024 was $4.5 million, down 82.97%.
  • Receivables for Q3 2025 was $13.3 million at Dna X, up from $12.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $32.0 million in Q3 2023 to a low of $4.5 million in Q4 2024.
  • The 5-year median for Receivables is $13.3 million (2025), against an average of $14.8 million.
  • The sharpest move saw Receivables skyrocketed 321.31% in 2023, then crashed 82.97% in 2024.
  • Year by year, Receivables stood at $13.1 million in 2021, then soared by 89.17% to $24.7 million in 2022, then rose by 7.43% to $26.5 million in 2023, then crashed by 82.97% to $4.5 million in 2024, then soared by 195.11% to $13.3 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $13.3 million, $12.5 million, and $5.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.